Office of Drug Evaluation II Director Curtis Rosebraugh will be retiring from the US FDA effective April 28 at a time when two of the three review divisions he oversees are also undergoing leadership changes.
Division of Pulmonary, Allergy, and Rheumatology Products Director Badrul Chowdhury left FDA April 16 for a position at AstraZeneca and...






